Skip to content
EmbarkNeuro
About
About Us
Our Team
Board of Directors
Scientific Advisors
Our Science
Rooted in Biology
Publications & Presentations
Clinical Trials
News
Careers
Contact
Our Science
Publications & Presentations
April 12, 2023
Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorder
December 5, 2022
American College of Neuorpsychopharmacology
September 19, 2022
ANC 501: A Novel V1b Receptor Antagonist for Major Depressive Disorder
May 1, 2021
Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data
May 1, 2021
Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study
